Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

CuraCell granted approval for trial of new therapy for metastatic cancers

August 13, 2025 Research and Development CuraCell, Immunology, clinical trial, immunotherapy, metastic cancer

Swedish immunotherapy company, CuraCell, has received approval from the Paul-Ehrlich-Institut in Germany to begin a phase 1/2a clinical trial of …
News
eye1

Eyestem secures $10m to advance cell therapy for advanced eye disease

August 13, 2025 Medical Communications, Research and Development Eyestem, Opthalmology, cell therapy, dry age-related macular degeneration, geographic atrophy

Indian cell therapy company, Eyestem Research, has raised $10m in a funding round to support development of its investigational retinal …
News

Enzymatica appoints Sana Alajmovic as new CEO

August 12, 2025 Research and Development Corporate, Enzymatica, Infections and infestations

The board of directors of Enzymatica has appointed Sana Alajmovic as chief executive officer, succeeding Claus Egstrand. Egstrand will step …
Appointment
bonecells

OS Therapies advances regulatory pathway for bone cancer therapy

August 11, 2025 Medical Communications, Research and Development European Medicines Agency’, Medicines and Healthcare products Regulatory Agency, OS Therapies, Oncology, Orthopaedics, US Food and Drug Administration’, bone cancer, osteosarcoma

OS Therapies has announced significant progress in its regulatory strategy for OST-HER2, its lead immunotherapy candidate for preventing or delaying …
News

ARTBIO expands board and establishes technical advisory board

August 11, 2025 Medical Communications, Research and Development ARTBIO, Corporate, Oncology, advisory board, radiopharmaceuticals

ARTBIO, a radiopharma company developing radioligand therapies (RLTs), has appointed four new members to its board of directors and formed …
Appointment
pills-384846_960_720

Lilly reports positive results from trial of obesity candidate

August 8, 2025 Medical Communications, Research and Development Eli Lilly and Company, Obesity, cardiovascular risk, high blood pressure, obesity

Eli Lilly and Company (Lilly) has announced topline results from its phase 3 ATTAIN-1 trial, showing that orforglipron – a …
News

Horus Pharma expands distribution in North Africa and the Middle East

August 8, 2025 Mergers and Acquisitions, Research and Development Corporate, Horus Pharma, Opthalmology, distribution agreement

Ophthalmology company, Horus Pharma, based in Nice, France, has extended its global presence through new distribution agreements across eight countries …
News
drug-trials

Faron reports increased remission rate in trial for myelodysplastic syndrome candidate

August 7, 2025 Medical Communications, Research and Development Faron Pharmaceuticals, Oncology, US Food and Drug Administration, acute myeloid leukemia, myelodysplastic syndrome

Faron Pharmaceuticals has reported a rise in complete remission (CR) rates among patients with frontline high-risk myelodysplastic syndrome (HR-MDS) in …
News
hospital

Sanome’s AI tool gains certification for early detection of hospital infections

August 7, 2025 Business Services, Research and Development AI, Devices, Infections and infestations, Medicines and Healthcare products Regulatory Agency, NHS, Sanome, hospital-acquired infections

Sanome’s MEMORI, an artificial intelligence (AI) medical device that can predict hospital-acquired infections up to 72 hours before they present, …
News

PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit

August 7, 2025 Medical Communications, Research and Development Bioshares Biotech Summit, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis, neurodegenerative diseases

French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic Lateral Sclerosis (ALS) at the …
News
lungs

M42 study highlights positive performance of AI model for tuberculosis screening

August 6, 2025 Research and Development AI, Infections and infestations, M42, X-ray, tuberculosis

Healthcare tech company, M42, has published results from one of the largest real-world studies of an artificial intelligence (AI)-powered tuberculosis …
News
brain-770044_960_720

Lilly’s drug for early Alzheimer’s shows promising results

August 6, 2025 Medical Communications, Research and Development Alzheimer's, Eli Lilly, Neurology, dementia

Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase 3 study, showing that Kisunla …
News
blood-1813410_960_720

FDA grants orphan drug designation to relapsed or refractory multiple myeloma candidate

August 6, 2025 Medical Communications, Research and Development Oncology, Sanofi, US Food and Drug Administration, myeloma

The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, Sanofi’s investigational monoclonal antibody developed for …
News

Freya Pharma launches phase 2 study of therapy for female sexual dysfunction

August 5, 2025 Research and Development Female Sexual Interest/Arousal Disorder (FSIAD), Freya Pharma Solutions, Genito-Urinary system, sexual health

Freya Pharma Solutions has announced the initiation of a phase 2 study evaluating its Lybrido to treat female sexual interest/arousal …
News

Hansa Biopharma announces positive data for Duchenne muscular dystrophy gene therapy

August 4, 2025 Research and Development Duchenne Muscular Dystophy, Hansa Biopharma, Rare Diseases, Sarepta Therapeutics, clinical trial, genetic disorder

Hansa Biopharma has announced encouraging results from its ongoing SRP-9001-104 trial, which is investigating the use of imlifidase as a …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025